PubMed Health⌕ Search

Biomedical subjects

V L Vinokurov

Publications and source records attributed to V L Vinokurov.

At least 19 recordsLinked to original sources
PubMed2006

[Combined use of local and systemic radiomodifiers as a new modality of cervical carcinoma therapy].

A cooperative study included 643 cervical carcinoma patients (stage II-III). Radiotherapy used such local and systemic radiomodifiers as DMSO-dissolved metronidazole, which inhibited allopurinol DNA reparations, and dipyridamol, an inductor of interferon synthesis. A 13-15% rise in survival matched the results of combined treatment for cervical carcinoma, yet the simplicity of operation, accessibility, high efficiency and stability of results of our modality made it quite competitive in therapy of the disease.

Adult↗
PubMed2004

[Role of endovascular radiologic component in the combined therapy of locally advanced cervical carcinoma].

Data are presented on the treatment of 308 patients with cervical carcinoma stage II-IV. Standard combined therapy was given to 143 patients in control. The study group (165) received radiotherapy in conjunction with roentgeno-endovascular occlusion of the internal ileal arteries and/or regional chemotherapy. Use of the latter modality was followed by a significant rise in remissions and higher survival rate (58%) as compared with 45.9% in control.

Adult↗
PubMed1992

[The indications for second-look laparotomy in ovarian cancer patients].

Data on 304 patients with ovarian malignancies (mostly epithelial-72.0%) who had undergone second-look surgery were analysed to develop indications and assess the clinical value of the procedure. Second-look operations were performed 10-22 months after primary surgery in the following clinical settings: (1) clinical remission if wash-offs from the Douglas' pouch peritoneum revealed tumor cells or a high blood-CA-125 level was established (8 patients with stage I-II cancer), (2) remission after 6-10 courses of combination chemotherapy (13 patients with stage III-IV tumor), (3) remission following non-radical primary surgery (117 cases), (4) patients with suspected relapse (144), and (5) cases who were not suspicious for relapse but required laparotomy for concomitant surgical pathology such as, for instance, ventral hernia (22). Intra- and postoperative complications were encountered in 29 out of 304 (9.5%) patients and operative lethality rate was 0.9%. It was shown that improvement in noninvasive methods of monitoring allows to limit indications for second-look surgery in stage III cancer.

Adenocarcinoma↗
PubMed1992

The controversial 'second-look' laparotomy.

To determine optimal indications for and clinical assessment of the significance of relaparotomy, the data of 304 women with malignant ovarian tumours (of epithelial origin, predominantly, 72%) who had undergone a 'second-look' operation were analysed. 'Second-look' relaparotomies were performed 10-22 months after the initial operation, on the following clinical indications: 1) clinical remission after initial combined treatment (surgery + chemotherapy) in cases where malignant cells are found at systematically performed cytological examinations of ??? or lavage from peritoneal surfaces of the Douglas cul-de-sac plus high levels of CA 125 in blood serum (8 patients with stages I and II, FIGO classification); 2) remission after adequate combined treatment and following 6-10 cycles of polychemotherapy, in order to decide whether to abandon or continue with treatment (13 patients with stages III and IV); 3) clinical remission following initial operation which was voluminously non-radical (117 patients); 4) suspicion of tumour recurrence after adequate combined treatment (114 patients); 5) no suspicion of cancer recurrence, though with ventral hernia or other pathology requiring relaparotomy (22 patients). Complications arising at the 'second-look' operation or during the postoperative period were observed in 29 of the 304 patients (9.5%), giving a postoperative mortality of 0.9%. According to experience, the positive significance of 'second-look' operations to optimize treatment of patients with malignant ovarian tumours is obvious.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1992

Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors.

The concentration of CA 125 was defined in the blood serum of 151 patients with ovarian tumors: benign--49, borderline--5 and malignant--97. In 75.7% of benign tumors CA 125 concentrations did not exceed the normal level. In two from five patients with borderline tumors CA 125 concentration varied from 47 to 130 U/ml. High levels of CA 125 (from 125 to 10.000 U/ml and higher) were revealed in 54 from 57 patients (94.7%) with malignant ovarian tumors. If in Stages I and II elevated CA 125 levels (from 125 to 430 U/ml) were discovered in 71.4% and 80.0% of the cases, respectively, then in Stages III and IV CA 125 levels rose from 300 to 10.000 U/ml and higher in all cases. High CA 125 concentrations were noticed in 95.7% of patients with clinical signs of recurrences of the disease, and it was proved at "second-look" surgery. Thus, it was expedient to use CA 125 widely for an early detection of ovarian cancer, as a control on the efficiency of therapy and in diagnosis of subclinical recurrences of the disease.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1991

[Clinical studies of radiation-sensitizing effects of metronidazole in patients with cancer of the uterine body].

The local use of MZ solved in DMSO makes it possible to reach high MZ concentrations (by order 6000-8000 mu g/g) in tumor tissue in the absence of a toxic effect of the drug resulting from its small doses. The results of investigation of radiation pathomorphosis show that the local use of MZ solved in DMSO enhances the damaging effect of radiation on a tumor. Some traits revealed in MZ diffusion (a raised concentration at the serous membrane) must undoubtedly lead to increased efficacy of radiation exposure in zones, responsible for local therapeutic failures. It will permit a considerable increase in the efficacy of radiation therapy of patients with cancer of the uterine body.

Dimethyl Sulfoxide↗
PubMed1990

[Methods of optimizing and objective criteria for evaluating the efficacy of chemo-surgical treatment of malignant epithelial tumors of the ovaries].

In a group of 811 patients with epithelial malignancies of the ovaries, the diagnostic and therapeutic procedures used were either standard or they involved elements of optimization based on certain objective criteria. The reliability of diagnosis and treatment efficacy in the two subgroups were compared. Stage I-II tumors made up 37.1% of neoplasms diagnosed at regular check-ups and 16.9% of those identified in controls. Duration of relapse-free period was 45.0 and 11.8 months whereas five-year survival rate--42.9% and 20.5%, respectively. Clinically inapparent recurrence was cytologically detected in 29.5% of "actively" followed patients. Additional estrogen and progestin therapy assured an increase in recurrence-free period from 13.5 to 20.6 months in patients with stage III-IV tumors (9.1 and 9.5 months in controls). The efficacy of single-agent and combination chemotherapy in stage III-IV cancer was nearly the same. Adjuvant postoperative chemotherapy administered during the first 2.5-3 years of remission resulted in a 2.2--fold decrease in recurrence rate and a 21.4% rise in five-year survival rate in patients with stage Ia and Ib cancer.

Adenocarcinoma↗
PubMed1990

[Alterations of c-myc and c-Ha-ras-1 oncogenes in human ovarian cancer].

Fourteen cases of the ovarian carcinoma (OC) were studied for alterations of c-myc and c-Ha-ras-1 oncogens. Amplification of c-myc was found in four aggressive and widespread OC. An increased frequency of one of the four common alleles of c-Ha-ras-1-allele A4-was determined in OC patients. Rearrangements of c-Ha-ras-1-allelic deletions and change in the allele fragment length-were found in all OC with A4 allele. In contrast, no alterations were detected in tumours without allele A4. Thus allele A4 of c-Ha-ras-1 may be viewed as a genetic marker of predisposition to OC in combination with other clinical parameters. Alterations of c-myc and c-Ha-ras-1 oncogens were observed in 8 out of 14 OC samples suggesting that the development of this type of human neoplasm is due to rearrangements of these genes.

Alleles↗
PubMed1989

[Treatment of patients with marginal tumors of the ovary].

The clinico-morphological data on the results of five- and ten-year follow-up of 228 patients suffering "borderline" epithelial (serous, mucinous and endometrioid) ovarian tumors were studied. Considerations of choice of optimal treatment procedure versus degree of clinical and morphological malignancy, tumor histotype and age are discussed.

Adenoma↗
PubMed1986

[Cellular immunity indices of ovarian cancer patients].

The dynamics of functional indexes of T-cell immunity was studied in 47 patients with extended ovarian tumor. The said parameters were found to be adversely affected in primary patients as a result of surgery and chemotherapy. They came back to normal during remission but were badly deranged in relapsing patients.

Female↗
PubMed1986

[Outpatient care of patients with ovarian cancer after primary treatment and the prevention of recurrence].

According to the scheme worked out by the staff of the 1st oncogynecologic department of the Institute, all patients with ovarian cancer in whom primary treatment was effective should be followed up. Clinical and cytologic examination should be carried out every 2 months during the first 1.5-2 years when recurrence is most likely to develop. Thereafter, cytologic follow-up (every 3 to 4 months) should be continued. Second-look operations should be carried out on a wider scale in suspicious cases. Prevention of recurrence should be assured by adequate primary treatment of ovarian cancer, particularly, at early stage and regular posttreatment check-ups.

Adult↗
PubMed1986

[Factors affecting the incidence of metastasis of malignant epithelial tumors of the ovaries].

Clinico-morphological data on 714 cases of epithelial ovarian malignancy were evaluated. 558 patients (78.2%) revealed metastases at various sites in the course of primary treatment. Frequency of dissemination was significantly higher in patients over 40 years, postmenopausal ones and those with a shorter history of disease (duration of symptoms). A significantly higher frequency of metastatic spread was also observed in cases of bilateral involvement of the ovaries, invasion through the tumor capsule and into adjacent tissues and organs, adhesions, ascitis, hydrothorax, cystic-solid, solid and papillary growth patterns (vs relatively lower frequency for cystic tumors). Histologic type of tumor was of major importance, too.

Adult↗
PubMed1985

[The degree of differentiation and the clinical course of ovarian cancer].

Clinical course versus morphological data on the level of tumor cell differentiation was studied in 323 cases of cancer of the ovaries. Level of cell differentiation proved to be of prognostic value, since it appeared to influence prognosis and clinical course greatly. Metastasis developed in 58.2 +/- 4.5% of patients suffering well-differentiated ovarian cancer. In cases of moderately- and poorly-differentiated cancer, it was 76.1 +/- 5.1 and 90.8 +/- 2.5%, respectively. The high level of tumor cell differentiation was registered in 41.8 +/- 4.5% of patients with cancer at early stages (I and II), while the low--level--in 9.2 +/- 2.5% only. This was matched by the predominance of poorly--differentiated tumors over those with high level of cell differentiation (90.8 +/- 2.5 and 58.2 +/- 4.5%, respectively). The five-year survival rate in patients with poorly--differentiated tumors was 8.3 +/- 2.5%, i. e. 7.8 times lower than in cases of tumors with high level of cell differentiation.

Adenocarcinoma↗